Showing posts with label S100B protein. Show all posts
Showing posts with label S100B protein. Show all posts

Tuesday, 31 January 2017

S100B protein and autism continued

"Our findings showing an increase in peripheral concentrations of S100B and TNF-α provide limited support to the hypothesis about the roles of altered immune function and S100B in autism spectrum disorder (ASD)."

So said the findings reported by Selin Aktan Guloksuz and colleagues [1] (open-access available here) continuing some discussions a few years back on a possible role for S100B in relation to at least some autism (see here).

S100B - S100 calcium-binding protein B - is a compound involved in quite a few biological reactions not least "as a biomarker of global glial activity." Elevations of the S100B have been reported in relation to several states including that of [traumatic] brain injury. Outside of some research suggesting that elevations of S100B might also be a feature of diagnoses such as schizophrenia (see here), it has also been the topic of investigations with [some] autism in mind [2] too. The name of the game is elevations in S100B in relation to autism and more.

Based on analyses of fasting blood samples from "40 unmedicated children with autism" (where autism diagnoses were confirmed by study researchers) and 35 asymptomatic control children, researchers measured levels of plasma S100B alongside various markers of immune function (cytokines). Among the suite of cytokines examined, levels of "tumor necrosis factor alpha (TNF-α), interferon gamma, interleukin (IL)-1β, IL-4, IL-6, IL-10, and IL-17A" were included. The idea of using unmedicated children with autism stems from the suggestion that at least one medication used for some autism might have the ability to elevate S100B [3].

Results: as per the opening sentence to this post, levels of S100B and TNF-α were 'different' between the groups (both elevated) and this finding remained "after controlling for age, sex, and BMI [body mass index]." Researchers also reported some results looking at whether ASD symptom presentation might show any 'association' with S100B levels. On this topic they reported that: "Plasma S100B concentrations in children with severe ASD symptoms were higher than in children with mild-moderate ASD symptoms" but when again controlling for age, sex and BMI this association did not hold (significantly). As for the other cytokines outside of TNF-α... nothing came up as significant between the groups. This is interesting in light of recent work (see here) and even Guloksuz et al talk about future "prospective longitudinal studies investigating a broad set of immune markers, both in serum and CSF [cerebrospinal fluid], in large samples" and the pros- and cons of looking in CFS.

Where next for this area of investigation? Well, taking into account the link between S100B and brain injury and what that could mean for cognitive processes for example, I'd be minded to suggest that more study is needed looking at the effect of S100B levels in relation to cognition and autism. Take for example the study results from Chen and colleagues [4] who reported that "serum S100B level was an independent contributor to the global cognitive dysfunctions, particularly for the speed of processing, attention/vigilance, visual learning and reasoning/problem solving subscores" in their cohort of participants with schizophrenia. Might similar correlations be present alongside S100B elevations in relation to autism? I'd also be minded to suggest looking at a possible role for comorbidities potentially accompanying a diagnosis of autism as being important for S100B elevations in light of other research on depression for example [5]. Depression (various types) and autism is very much an important area of overlap (see here for example) and might actually offer at least one way to target elevations in S100B.

There is more to do on this topic.

----------

[1] Guloksuz SA. et al. Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders. Rev Bras Psiquiatr. 2017 Jan 12:0.

[2] Al-Ayadhi LY. & Mostafa GA. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. J Neuroinflammation. 2012 Mar 16;9:54.

[3] Quincozes-Santos A. et al. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol Cell Biochem. 2008 Jul;314(1-2):59-63.

[4] Chen S. et al. Cognitive dysfunction correlates with elevated serum S100B concentration in drug-free acutely relapsed patients with schizophrenia. Psychiatry Res. 2017 Jan;247:6-11.

[5] Rajewska-Rager A. & Pawlaczyk M. The role of S100B protein as a potential marker in affective disorders. Psychiatr Pol. 2016;50(4):849-857.

----------

ResearchBlogging.org Guloksuz SA, Abali O, Aktas Cetin E, Bilgic Gazioglu S, Deniz G, Yildirim A, Kawikova I, Guloksuz S, & Leckman JF (2017). Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) PMID: 28099628

Friday, 3 October 2014

S100B and schizophrenia meta-analysed

I don't know if it's just me but this year (2014) I seem to be covering a lot more meta-analysis papers on this blog. I assume that's because of the increasing volume of peer-reviewed research being created year-on-year leading to greater volumes of research fodder for such grand reviews. Whatever the reason(s), there are some really interesting conclusions being reached in that literature as per the meta-analysis by Aleksovska and colleagues [1] (open-access) focusing on S100B blood levels and schizophrenia.
"My name is Gladiator"

I've talked about S100B previously on this blog in relation to autism (see here) including some of the possible whys and wherefores. Very briefly, S100B - S100 calcium binding protein B - is a protein primarily secreted by glial cells which seems to be involved in various important functions including those in relation to synaptic plasticity and the innate immune response among others. S100B levels have also been examined in relation to brain injury, although some uncertainty seems to persist about their value here [2].

With schizophrenia in mind, there is a growing research base suggestive of some role for S100B in the condition (see here). Not all the evidence has universally pointed to a connection between protein and condition, bearing in mind the similar issue of heterogeneity and 'spectrums' being discussed in schizophrenia circles as they have in autism circles (albeit with caveats).

The Aleksovska paper reported that based on their analysis of the combined literature (using the PRISMA guidance) "S100B in peripheral blood was significantly increased in schizophrenia patients, with an almost double level in cases than controls". Results drawn from 20 studies which survived their filtering (all case-control reports) also indicated: "no evidence of difference in subgroups regarding detection of S100B in plasma or serum, medication status, stage of the disease, ethnicity, selection of cases and controls and source of controls". Interestingly too, the authors make reference to the "the traditional reductionist assessments based on single-pathways analyses and categorical diagnoses" used in schizophrenia as not being all that useful. They call their alternative 'Systems Medicine'. I would say however that they're describing something like RDoC (see here).

What's more to say on this area of schizophrenia research? Well, further investigations on the reason(s) for elevated S100B might be a good starting point including that related to glial cell activation in relation to schizophrenia [3]. But... and it is an important point, investigations also need to consider the variety of other factors which might account for elevated levels of S100B and are comorbid to psychiatric symptoms such as weight and insulin resistance [4], potentially all the more pertinent in light of the findings from van Beveren and colleagues [5] discussed in a recent post (see here).

Music to close. Cue the 70's detectives... Sabotage.

----------

[1] Aleksovska K. et al. Systematic Review and Meta-Analysis of Circulating S100B Blood Levels in Schizophrenia. PLoS One. 2014 Sep 9;9(9):e106342.

[2] Hansen-Schwartz J. & Bouchelouche PN. Use of biomarker S100B for traumatic brain damage in the emergency department may change observation strategy. Dan Med J. 2014 Sep;61(9):A4894.

[3] Rothermundt M. et al. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):361-4.

[4] Steiner J. et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry. 2010 Jan;15(1):3-4.

[5] van Beveren NJ. et al. Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry. 2014 Aug 26;4:e430.

----------

ResearchBlogging.org Aleksovska K, Leoncini E, Bonassi S, Cesario A, Boccia S, & Frustaci A (2014). Systematic Review and Meta-Analysis of Circulating S100B Blood Levels in Schizophrenia. PloS one, 9 (9) PMID: 25202915

Sunday, 22 April 2012

S100B protein and autism

I am a little late getting to this paper given that other bloggers have discussed some of the ins and outs of its content and potential implications for autism spectrum conditions. Hopefully I can add some additional value to this area of endeavour with this post.

I freely admit that until the paper by Al-Ayadhi and Mostafa* was published I had never come across the S100B protein ever. Indeed had someone asked me 'what is the S100B protein' I might have been tempted to say either some kind of experimental protein shake or perhaps some elaborate lab-grown meat alternative as per this story.

As it happens S100B protein is a member of the S100 proteins, so named because the protein is 100% soluble in ammonium sulphate at neutral pH. S100B protein is synthesised in quite considerable amounts by astrocytes and has been tied into various functions including long-term neuronal synaptic plasticity. At elevated levels however, S100B protein has been associated with neuronal death among other things as per this study looking at levels in Olympic boxers.

With this in mind together with some speculation on a link with autoimmunity, or more specifically autoantibodies tied into neurological damage, the authors set about looking at S100B as a marker of potential neurological damage combined with antiribosomal P protein antibodies. For those avid viewers, antiribosomal P protein antibodies have already been looked at by this Saudi autism research group before, specifically with plasma neurokinin A levels in mind.

A summary of the current paper:

  • Sixty-four children diagnosed with DSM-IV autism, mean age 8.4 years were included for study and compared against 46 age- and sex-matched asymptomatic controls.
  • Serum levels of S100B protein were measured by ELISA. Actually, samples were all analysed twice just to make sure there was some degree of consistency in the findings. At the same time, serum IgG and IgM antiribosomal P protein antibodies were also measured. ELISA relies on the principle of antibody-antigen interaction which can sometimes be affected by cross-reactivity. In this study, such confounders were not observed in any significant measure.
  • The results: serum levels of S100B protein were elevated in the autism group compared to controls (p<0.001). There was quite a bit of overlap between the groups so no AUC=1 for this study group this time around. Based on CARS scores, severity of autism also seemed to be a factor: more severe cases seemed to show elevated levels compared with milder or moderate cases (according to CARS).
  • Increased serum levels of antiribosomal P protein antibodies were also reported in the autism group compared with controls and again severity of CARS autism was also a factor.
  • When it came to plotting any correlation between the two variables, S100B and antiribosomal P protein antibodies, it was a case of close but no statistical cigar.

These results are interesting insofar as the main findings suggestive of increased serum levels of S100B in autism and a kind of sliding scale involvement when taking severity of presented symptoms into account. I would hasten to add that S100B protein has also cropped up in other conditions including schizophrenia and bipolar disorder although questions about whether this is a central finding or perhaps related to issues with glucose metabolism for example, remain unanswered. I note for example, markers of body weight and body mass were not recorded in the recent study thus remaining a potential confounding variable.

Alongside the other research being undertaken by this group with autism as a specific focus, a fuzzy picture is starting to be built up of quite a complex relationship between the immune system, various neurological functions and autism, at least in the small numbers of cases included in their studies.

To finish, I was torn between 2 songs for this post. Instead of deciding I offer a choice: The Pixies and Monkey gone to heaven or The Descendents and I'm the one. It's your choice.

* Al-Ayadhi L. & Mostafa GA. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. Journal of Neuroinflammation. March 2012.
DOI: 10.1186/1742-2094-9-54